Talis Biomedical Corporation
TLIS · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $60 | $70 | $77 | $88 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $1 | $1 | $2 |
| Total Curr. Assets | $64 | $71 | $78 | $90 |
| Property Plant & Equip (Net) | $8 | $10 | $15 | $16 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $1 | $2 | $2 | $2 |
| Tax Assets | $0 | $0 | $4 | $0 |
| Other NC Assets | $0 | $0 | $2 | $0 |
| Total NC Assets | $9 | $11 | $21 | $18 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $73 | $82 | $98 | $107 |
| Liabilities | – | – | – | – |
| Payables | $4 | $4 | $1 | $3 |
| Short-Term Debt | $6 | $6 | $6 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | -$4 | $0 | $0 | $0 |
| Other Curr. Liab. | $2 | $0 | $2 | $3 |
| Total Curr. Liab. | $8 | $9 | $9 | $8 |
| LT Debt | $16 | $16 | $17 | $17 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $16 | $16 | $17 | $17 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $19 | $19 | $20 | $20 |
| Total Liabilities | $24 | $26 | $29 | $26 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$562 | -$553 | -$540 | -$527 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $610 | $610 | $609 | $608 |
| Total Equity | $49 | $57 | $69 | $82 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $73 | $82 | $98 | $107 |
| Net Debt | -$38 | -$48 | -$54 | -$68 |